Personalised Cancer Medicine Flashcards 2022
Indications determined by the organ of origin
Pancreatic Cancer
Standard
Recommended
Currently not recommended
- Germ-line BRCA 1-2
- Microsatellite Instability*
- NTRK
- ATM, PALB2, p53, KRAS, CDKN2, SMAD4, MLL3, TGFBR2, ARID1A, ALK, BRAF, HER2, ROS, RRG1
* by either IHQ (MLH1, PMS2, MSH2 and MSH6) or by genomic study (BAT25 and BAT26, D2S123, D5S346 and D17S250).
The Standard category is based on current treatment indications with approved funding by the Spanish National Health System.
The Recommended category is based on currentrecommendations by EMEA and FDA.
The Recommended category is based on currentrecommendations by EMEA and FDA.
References:
1. Curtin NJ, Drew Y, Sharma-Saha S. Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy. Nat Rev Clin Oncol. 2019 Dec;16(12):725-726. doi: 10.1038/s41571-019-0285-2.
2. de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440.
3. Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387.
